NRAS and melanoma: We selected Gamitrinib, a mitochondriotoxic small molecule, that selectively blocks mitochondrial HSP90 and exhibits broad anti-cancer activity including efficacy in BRAF-mutant melanoma, but limited activity in NRAS-mutant cells as a single agent [39].